PALATIN TECHNOLOGIES INC (PTN)

Palatin stock plunges 40% on mixed Phase 3 data for dry eye drug (NYSE:PTN)

Palatin Technologies (PTN) stock plunged 40% Wednesday after the company said a Phase 3 pivotal study for its drug PL9643 failed to meet a co-primary endpoint. Read more here.

The 3 Best Penny Stocks to Buy in February 2024

With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies.

7 Analyst-Backed Stocks With Promising 10-Bagger Potential

Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot.

Palatin to raise ~$10M via securities offering

Palatin (PTN) announces a registered direct offering of approximately 1.83 million shares at $5.46 per share, alongside a concurrent private placement of...

3 Penny Stocks to Buy to Unlock 2,500% Upside Potential

These penny stocks have triple-digit upside as 2024 brings easing monetary policy and economic normalization.

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Friday Sector Laggards: Biotechnology, Rubber & Plastics

Analysts Say 3 Stocks Have a Combined Upside of 3000%

These high-risk, high-reward bets could be at an inflection point before their growth takes off next year.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to dive into the biggest pre-market stock movers for Friday morning as we check out the winners and losers today!

Palatin Technologies files to sell 2.48M shares of common stock for holders (NYSE:PTN)

Read about Palatin Technologies (PTN) filing a prospectus for the offer and sale of 2,476,416 shares of common stock by selling stockholders.

Palatin falls on common stock and warrants offering (NYSE:PTN)

Palatin Technologies (PTN) announces a direct offering of 2.358M common shares at $2.12 per share, along with warrants and a closing date of October 24,...

Palatin says preliminary Q1 gross product revenue for Vyleesi was $4.6M (NYSE:PTN)

Palatin Technologies said Thursday its preliminary gross product revenue for Vyleesi was $4.6 million for the first quarter of fiscal 2024. Read more.

Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

/PRNewswire/ -- The Melanocortin Receptor 4 (MC4R) is a protein-coupled receptor primarily expressed in the central nervous system, playing a pivotal role in...

Palatin receives notice of non-compliance from NYSE American (NYSE:PTN)

Palatin Technologies receives notice of non-compliance from NYSE American due to inadequate stockholders' equity, but no immediate impact on stock trading.

Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END

Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year's End

/PRNewswire/ -- About 9.4% of the world population is aged 65 or above. Older people typically consume more medicines than the people in other age group...

Palatin's Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China (NYSE:PTN)

Palatin Technologies (PTN) Tuesday announced that Fosun Pharma, the licensee of Vyleesi in China, reported its first sale in the Hainan Province of China.Palatin also announced that...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day off right with a breakdown of the biggest pre-market stock movers traders need to watch on Thursday!